Tags

Type your tag names separated by a space and hit enter

Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients.
Rev Clin Esp (Barc). 2013 Nov; 213(8):377-84.RC

Abstract

BACKGROUNDS AND OBJECTIVE

There are different second line glucose lowering drugs whose efficacy, safety and economic profile have not been established in our setting. We have analyzed the clinical (diabetic treatment adherence, metabolic control, hypoglycemia and macrovascular complications) and economic (resource use and costs) consequences of the combination of metformin with dipeptidyl peptidase inhibitors (DPPIV) in patients with type 2 diabetes.

PATIENTS AND METHODS

We conducted a multicenter, observational and retrospective study. Patients ≥30 years treated with metformin who initiated a second antidiabetic treatment during 2008-2009 were enrolled in the study. Two groups of patients were established: a) metformin with DPPIV and metformin with other diabetic drugs. The main measurements were comorbidity, compliance/persistence, metabolic control (glycosylated hemoglobin <7%), complications (hypoglycemia, macrovascular) and total costs. Patients were followed-up for 2 years.

RESULTS

A total of 2,067 patients were enrolled (mean age: 66.6 years, 53.1% male). Of these, 519 patients (25.1%) were analyzed in the metformin+DPPIV group and 1,548 patients (74.9%) in the group metformin+other antidiabetic drug. The DPPIV group patients showed better compliance (70.3 vs. 59.6%), persistence (63.4 vs. 51.0%) and metabolic control (64.3 vs. 59.6%), respectively (P<.001) compared to the other group. They also showed a lower proportion of hypoglycemia (13.9 vs. 44.3%), cardiovascular events (3.7 vs. 7.6%) and total costs (2,347 vs. € 2,682), P<.05.

CONCLUSIONS

Despite the limitations of the study, patients treated with metformin associated to DPPIV were more likely to show increased adherence, metabolic control and lower rates of hypoglycemia than those treated with metformin associated to other antidiabetics.

Authors+Show Affiliations

Dirección de planificación, Badalona Serveis Assistencials SA, Badalona, Barcelona, España. Electronic address: asicras@bsa.cat.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

Language

eng spa

PubMed ID

23870706

Citation

Sicras Mainar, A, et al. "Clinical and Economical Consequences of the Combination of Metformin With Dipeptidyl Peptidase Inhibitors in Type 2 Diabetes Patients." Revista Clinica Espanola, vol. 213, no. 8, 2013, pp. 377-84.
Sicras Mainar A, Roldán Suárez C, Font Ramos B, et al. Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. Rev Clin Esp (Barc). 2013;213(8):377-84.
Sicras Mainar, A., Roldán Suárez, C., Font Ramos, B., Navarro Artieda, R., & Ibáñez Nolla, J. (2013). Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. Revista Clinica Espanola, 213(8), 377-84. https://doi.org/10.1016/j.rce.2013.06.003
Sicras Mainar A, et al. Clinical and Economical Consequences of the Combination of Metformin With Dipeptidyl Peptidase Inhibitors in Type 2 Diabetes Patients. Rev Clin Esp (Barc). 2013;213(8):377-84. PubMed PMID: 23870706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. AU - Sicras Mainar,A, AU - Roldán Suárez,C, AU - Font Ramos,B, AU - Navarro Artieda,R, AU - Ibáñez Nolla,J, Y1 - 2013/07/17/ PY - 2013/03/18/received PY - 2013/05/28/revised PY - 2013/06/02/accepted PY - 2013/7/23/entrez PY - 2013/7/23/pubmed PY - 2014/12/17/medline KW - Cardiovascular disease KW - Control metabólico KW - Costes sanitarios KW - DPPIV KW - Diabetes KW - Eventos cardiovasculares KW - Health care costs KW - Hipoglucemias KW - Hypoglycemia KW - IDPP4 KW - Metabolic control SP - 377 EP - 84 JF - Revista clinica espanola JO - Rev Clin Esp (Barc) VL - 213 IS - 8 N2 - BACKGROUNDS AND OBJECTIVE: There are different second line glucose lowering drugs whose efficacy, safety and economic profile have not been established in our setting. We have analyzed the clinical (diabetic treatment adherence, metabolic control, hypoglycemia and macrovascular complications) and economic (resource use and costs) consequences of the combination of metformin with dipeptidyl peptidase inhibitors (DPPIV) in patients with type 2 diabetes. PATIENTS AND METHODS: We conducted a multicenter, observational and retrospective study. Patients ≥30 years treated with metformin who initiated a second antidiabetic treatment during 2008-2009 were enrolled in the study. Two groups of patients were established: a) metformin with DPPIV and metformin with other diabetic drugs. The main measurements were comorbidity, compliance/persistence, metabolic control (glycosylated hemoglobin <7%), complications (hypoglycemia, macrovascular) and total costs. Patients were followed-up for 2 years. RESULTS: A total of 2,067 patients were enrolled (mean age: 66.6 years, 53.1% male). Of these, 519 patients (25.1%) were analyzed in the metformin+DPPIV group and 1,548 patients (74.9%) in the group metformin+other antidiabetic drug. The DPPIV group patients showed better compliance (70.3 vs. 59.6%), persistence (63.4 vs. 51.0%) and metabolic control (64.3 vs. 59.6%), respectively (P<.001) compared to the other group. They also showed a lower proportion of hypoglycemia (13.9 vs. 44.3%), cardiovascular events (3.7 vs. 7.6%) and total costs (2,347 vs. € 2,682), P<.05. CONCLUSIONS: Despite the limitations of the study, patients treated with metformin associated to DPPIV were more likely to show increased adherence, metabolic control and lower rates of hypoglycemia than those treated with metformin associated to other antidiabetics. SN - 2254-8874 UR - https://www.unboundmedicine.com/medline/citation/23870706/Clinical_and_economical_consequences_of_the_combination_of_metformin_with_dipeptidyl_peptidase_inhibitors_in_type_2_diabetes_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2565(13)00222-1 DB - PRIME DP - Unbound Medicine ER -